JP4727925B2 - 統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン - Google Patents

統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン Download PDF

Info

Publication number
JP4727925B2
JP4727925B2 JP2003559986A JP2003559986A JP4727925B2 JP 4727925 B2 JP4727925 B2 JP 4727925B2 JP 2003559986 A JP2003559986 A JP 2003559986A JP 2003559986 A JP2003559986 A JP 2003559986A JP 4727925 B2 JP4727925 B2 JP 4727925B2
Authority
JP
Japan
Prior art keywords
formula
compound
phenyl
acid
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003559986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514457A5 (enExample
JP2005514457A (ja
Inventor
グンター ヘルツェマン，
ヘルムート プルッヒャー，
カイ シーマン，
ヨアヒム ライブロック，
ハルトムート グライナー，
クリスタ ブルガー，
メルヒナー， ラウリー フォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2005514457A publication Critical patent/JP2005514457A/ja
Publication of JP2005514457A5 publication Critical patent/JP2005514457A5/ja
Application granted granted Critical
Publication of JP4727925B2 publication Critical patent/JP4727925B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003559986A 2002-01-17 2002-12-17 統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン Expired - Fee Related JP4727925B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10201550.3 2002-01-17
DE10201550A DE10201550A1 (de) 2002-01-17 2002-01-17 Phenoxy-Piperidine
PCT/EP2002/014389 WO2003059882A1 (de) 2002-01-17 2002-12-17 Phenoxy-piperidine zur behandlung von erkrankungen wie schizophenie und depression

Publications (3)

Publication Number Publication Date
JP2005514457A JP2005514457A (ja) 2005-05-19
JP2005514457A5 JP2005514457A5 (enExample) 2006-02-09
JP4727925B2 true JP4727925B2 (ja) 2011-07-20

Family

ID=7712334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003559986A Expired - Fee Related JP4727925B2 (ja) 2002-01-17 2002-12-17 統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン

Country Status (11)

Country Link
US (2) US20050131021A1 (enExample)
EP (1) EP1465868A1 (enExample)
JP (1) JP4727925B2 (enExample)
CN (1) CN1615297A (enExample)
AU (1) AU2002358735B9 (enExample)
CA (1) CA2473409C (enExample)
DE (1) DE10201550A1 (enExample)
HU (1) HUP0500497A2 (enExample)
PL (1) PL373946A1 (enExample)
WO (1) WO2003059882A1 (enExample)
ZA (1) ZA200406504B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR046783A1 (es) * 2003-12-03 2005-12-21 Glaxo Group Ltd Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US8787440B2 (en) * 2008-07-25 2014-07-22 Qualcomm Incorporated Determination of receive data values
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
US8952169B2 (en) 2012-05-22 2015-02-10 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
CN104797555B (zh) 2012-07-06 2017-12-22 基因泰克公司 N‑取代的苯甲酰胺及其使用方法
HK1213476A1 (zh) 2013-03-14 2016-07-08 基因泰克公司 取代的三唑並吡啶及其使用方法
CA2898680A1 (en) 2013-03-15 2014-09-18 Genentech,Inc. Substituted benzoxazoles and methods of use thereof
CA2931732A1 (en) 2013-11-27 2015-06-04 Genentech, Inc. Substituted benzamides and methods of use thereof
WO2016007534A1 (en) 2014-07-07 2016-01-14 Genentech, Inc. Therapeutic compounds and methods of use thereof
PE20180575A1 (es) 2015-05-22 2018-04-04 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
BR112018006189A2 (pt) 2015-09-28 2018-10-09 Genentech Inc compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
CN109071426A (zh) 2016-03-30 2018-12-21 基因泰克公司 取代的苯甲酰胺及其使用方法
WO2018072602A1 (en) 2016-10-17 2018-04-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
EP3759098A1 (en) 2018-02-26 2021-01-06 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776293A (en) * 1950-08-09 1957-01-01 Nopco Chem Co Improved hydrogenation process
US4216218A (en) * 1979-02-23 1980-08-05 American Hoechst Corporation Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
EG18188A (en) * 1986-05-01 1992-09-30 Pfizer Ltd Process for preparation anti-arhythmia agents
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents
US5169855A (en) * 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
US5202346A (en) * 1992-02-25 1993-04-13 American Home Products Corporation Piperidinyl and piperazinyl derivatives
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ZA9610741B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
HUP9904363A3 (en) * 1996-08-15 2000-12-28 Schering Corp Piperidine ether muscarinic antagonists and pharmaceutical compositions containing them
GB9725541D0 (en) * 1997-12-02 1998-02-04 Pharmacia & Upjohn Spa Amino-benzothiazole derivatives
DE10000739A1 (de) * 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP2002363159A (ja) * 2001-04-05 2002-12-18 Sankyo Co Ltd ベンズアミジン誘導体
US20040180401A1 (en) * 2002-05-24 2004-09-16 Neurion Pharmaceuticals, Inc. Methods of determining precise HERG interactions and designing compounds based on said interactions

Also Published As

Publication number Publication date
HUP0500497A2 (hu) 2005-08-29
WO2003059882A1 (de) 2003-07-24
CA2473409C (en) 2011-09-27
US20050131021A1 (en) 2005-06-16
EP1465868A1 (de) 2004-10-13
CN1615297A (zh) 2005-05-11
ZA200406504B (en) 2005-09-15
AU2002358735B2 (en) 2009-03-12
JP2005514457A (ja) 2005-05-19
DE10201550A1 (de) 2003-07-31
CA2473409A1 (en) 2003-07-24
US20090247584A1 (en) 2009-10-01
AU2002358735B9 (en) 2009-04-09
AU2002358735A1 (en) 2003-07-30
PL373946A1 (en) 2005-09-19

Similar Documents

Publication Publication Date Title
JP4727925B2 (ja) 統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン
US4943578A (en) Piperazine compounds
JP2008509953A (ja) ４−［［（７ｒ）−８−シクロペンチル−７−エチル−５，６，７，８−テトラヒドロ−５−メチル−４−６−オキソ−２−ピペリジニル］アミノ］−３−メトキシ−ｎ−（１−メチル−４−ピペリジニル）ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
WO2019141179A1 (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
TW200813010A (en) Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
JP2011516442A (ja) 筋ジストロフィーを治療するための化合物
RS20090137A (sr) Sulfonamid derivati kao adrenergijski agonisti i muskarinski antagonisti
JP2005525332A (ja) ５−ｈｔ６受容体アフィニティーを有するスルホニル化合物
CZ362599A3 (cs) Indazolamidové sloučeniny jako serotoninergní přípravky
EP0937715B1 (en) Tetrahydrobenzindole compounds
US20060122191A1 (en) N-(indolethyl-)cycloamine compounds
PT94070A (pt) Processo para a preparacao de derivados de piperazina
WO2009092284A1 (zh) 苯并环庚烯类衍生物、其制备方法及医药用途
TW202321232A (zh) 小分子sting拮抗劑
US5472966A (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
JP2005082508A (ja) ２−アルコキシ−６−アミノ−５−ハロゲノ−ｎ−（１−置換−４−ピペリジニル）ピリジン−３−カルボキサミド誘導体およびそれを含有する医薬組成物
WO1996026924A1 (en) Arylpiperidine and arylpiperazine derivatives and drugs containing the same
WO2025065506A1 (zh) 苯甲胺类化合物及其合成方法与应用
KR20000029564A (ko) 5ＨＴ2ｃ길항제및Ｄ2길항제를함유하는약제학적조성물
KR840002139B1 (ko) 벤조퀴놀리진의 제조방법
JP2008523026A (ja) ドーパミン−ｄ２受容体に関する親和力およびセロトニン再吸収部位の組み合わせを有するフェニルピペラジン類
WO1997043292A1 (en) New thiazolopyridines
PT95970B (pt) Processo de preparacao e acidos carboxilicos aza-heterociclicos substituidos em n e de composicoes farmaceuticas
TWI386392B (zh) 一種可作為過氧小體增生活化受體調控劑的磺酸基取代雙環化合物
JPS5970679A (ja) ベンゾチアジン誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110414

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140422

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees